Biotech, Roundup, cancer
Amgen Tries to “Personalize” Drug, VLST Snags Deal, Tobacco Money Backs Research, & More Seattle-Area Life Sciences News
Luke Timmerman 12/18/08
(Page 2 of 2)
a couple of clinical trials in Australia and Germany. All existing investors chose to re-up.
—Xconomy hosted its first event in Seattle, focused on the emerging opportunities to develop vaccines. If you couldn’t make it out on a cold December night, here’s a recap of what panelists Todd Patrick, Steve Reed, Chris Elias, and Denise Galloway had to say.
—ZymoGenetics CEO Bruce Carter, former Targeted Genetics chief Stewart Parker, and Gilead Sciences executive Bruce Montgomery shared some fascinating insights into the secrets of entrepreneurial success this week at a “fireside chat.” Luck, as it turns out, is no small factor.
—Redmond, WA-based Healionics raised $2.6 million from a syndicate of local angel investors. The company, which has its roots in work at the University of Washington, is working on technology to promote healing around implanted medical devices.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
